mRNA-1608

mRNA-1608 was Moderna's experimental vaccine for people who already had recurrent genital HSV-2. Moderna completed one early human study, then discontinued the program in 2025 and later said it had no current plans to continue development. No approved use or confirmed access pathway was identified in the checked sources through August 31, 2026.

The program can sound promising at first glance: it produced immune responses, and average outbreak counts were lower in each vaccine group than in the comparison group. But the public results do not include the analyses needed to show that the vaccine itself caused that difference.

mRNA-1608 was a therapeutic vaccine candidate. Here, “therapeutic” means it was studied in people who already had HSV-2, with the aim of reducing outbreaks and lowering how often HSV-2 was detected in genital samples. This measure is called genital shedding. It was not a vaccine for preventing infection in people without HSV.

It contained five pieces of messenger RNA (mRNA), each carrying instructions for an HSV-2 target intended to trigger an immune response. That design did not, by itself, show that the vaccine could prevent outbreaks.

The first question was safety: what reactions and adverse events occurred after vaccination? Researchers also measured immune responses, genital-herpes recurrences, lesion rate, and HSV-2 genital shedding to look for signs that the vaccine might affect the course of recurrent disease.

The study enrolled 303 adults aged 18–55 with recurrent genital HSV-2. Of those participants, 302 received at least one injection, 292 received both injections and were included in the main analysis, and 257 completed the study.

The trial started in September 2023 and completed follow-up in April 2025. Investigators presented interim results in October 2025, Moderna announced the program's discontinuation the following month, and final summary results appeared on ClinicalTrials.gov in May 2026.

On safety, the interim conference report said investigators had identified no safety concern through six months after the second dose and that most reactions participants were specifically asked to report were mild or moderate (grade 1 or 2). Later registry tables recorded events classified as serious for six mRNA-1608 recipients, with two in each dose group, and none in the 76-person comparison group. The registry does not report whether the vaccine caused those events and does not provide a comparative safety analysis.

All three mRNA-1608 dose groups showed increases in antibodies against three of the vaccine's HSV-2 targets. Investigators also reported other antibody and cellular immune responses. These results show immune activity; they do not by themselves show that participants had fewer outbreaks or less shedding.

The interim report described exploratory trends toward a later first recurrence and fewer recurrences. Final registry averages were numerically lower in every mRNA-1608 group than in the control group at six and 12 months. Results for lesion rate and HSV-2 shedding were mixed across doses and time points.

The public record does not include the planned analyses comparing the groups while accounting for the study design. The study's statistical plan also said no formal hypotheses would be tested. Without those comparisons and a clear measure of uncertainty, the available numbers do not establish that mRNA-1608 was effective.

The most defensible description is early human evidence. The study established that the candidate reached human testing and produced measurable immune responses. It did not publicly establish a comparative clinical benefit.

The study did not measure transmission to partners or elimination of latent HSV. It therefore does not show that mRNA-1608 prevented transmission or cured HSV.

As of August 31, 2026, mRNA-1608 was not an available treatment: no approved use or confirmed access pathway was identified, and Moderna said it had no current plans to continue development. Its value is as a historical record of what was tested, what was reported, and what remains unanswered.

Moderna listed mRNA-1608 among programs discontinued in 2025 and said the HSV program would not advance to Phase 3. Its 2025 annual report later said it had no current plans for future development of the listed programs.

The public record does not establish why mRNA-1608 specifically was stopped. Moderna's annual report referred to portfolio priorities and emerging clinical data across a group of discontinued programs, but it did not assign a clinical, safety, strategic, or commercial reason to mRNA-1608. The evidence supports “discontinued”; it does not support calling the program a clinical failure.

No later mRNA-1608 trial, named successor, confirmed licensing path, or regulatory next step was identified in the registry, publication, sponsor, regulatory, and filing routes checked through August 31, 2026.

That is a bounded finding, not a claim that the program could never be transferred, reconsidered, or followed by a future program. No such next step is currently confirmed in the checked record.